相关实验视频

Updated: Jun 7, 2025

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

发现了新型SIRT3抑制剂,用于通过结构修改进行癌症分化疗法

Honggang Li¹, Yanmei Du², Lihui Zhang³

¹School of Chemistry and Chemical Engineering, Shandong University of Technology, Zibo, Shandong, China.

Drug development research

|November 11, 2024

概括

新的SIRT3抑制剂促进多发性骨髓瘤 (MM) 细胞分化,提供潜在的癌症治疗. 化合物A7显示出显著的MM细胞正常化,并增强现有的癌症治疗方法.

科学领域:

生物化学生物化学
分子生物学分子生物学
在瘤学瘤学.

背景情况:

赛尔图因3 (SIRT3) 在癌症进展中起作用.
针对SIRT3进行癌症分化疗法是一种新兴的策略.
以前的化合物S27为结构修改提供了基础.

研究的目的:

为了发现多发性骨髓瘤 (MM) 癌症分化疗法的强有力的SIRT3抑制剂.
合成和评估基于S27结构的新型化合物.
评估这些抑制剂在促进MM细胞分化和增强抗癌作用方面的有效性.

主要方法:

在两个系列中设计和合成49种新型化合物.
酶抑制测试以确定SIRT3抑制活性和选择性.
关于MM细胞分化,抗原表达 (CD49e,IgLG) 和对生长因子 (IL-6) 和治疗药物 (Ixazomib) 的体外研究.

主要成果:

几种合成的化合物 (A7,A13,B15,B26) 显示出强有力的和选择性的SIRT3抑制.
化合物A7有效地促进了MM细胞向正常表型分化,增加了CD49e和免疫球蛋白轻链表达.
A7逆转了IL-6诱导的增殖,增强了Ixazomib的抗增殖作用,并在MM细胞中增加了Ixazomib诱导的亡.

结论:

成功开发出具有显著MM细胞分化能力的强效SIRT3抑制剂.
这些新型化合物显示出作为治疗多发性骨髓瘤的单疗法或组合疗法的前景.
这些发现支持SIRT3抑制作为癌症分化疗法的可行策略.

关键词:

在SIRT3中,SIRT3是最重要的.不同化的差异化差异化.多发性骨髓瘤是多发性骨髓瘤的一种.选择性抑制剂的选择性抑制剂结构的修改,结构的改变.

更多相关视频

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...